An interventional study of MedlyPeds App in Pediatric Heart Failure, Congenital Heart Disease (CHD) and Acquired Heart Disease, sponsored by The Hospital for Sick Children. Recruiting at 1 site in Canada. Open to participants aged 8 Years to 18 Years. Per ClinicalTrials.gov, last updated 2026-11-17.
Sponsored by The Hospital for Sick Children · Not applicable, Interventional, and Other
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 22 studies in Heart Defects, Congenital by The Hospital for Sick Children — 3 open to participants now, 3 under way, none of them phase 3. Heart Defects, Congenital · The Hospital for Sick Children.
Among the 22 studies in Heart Defects, Congenital by The Hospital for Sick Children, this one is the 16th largest by planned enrollment, is one of 2 that started in 2026, is one of 13 with no phase, and was the 21st registered.
992 studies on the registry are indexed under Heart Defects, Congenital; 252 are open to participants now.
Browse Heart Defects, Congenital studies →3 of the 22 studies in Heart Defects, Congenital by The Hospital for Sick Children are open now, in 1 country. Recruiting first, the newest first:
The Hospital for Sick Children · Sites in Canada
Ages 16+
The Hospital for Sick Children · Sites in Canada
Ages 3–9
By country, each count listing its studies:
Of the 156 Heart Defects, Congenital studies recruiting now, 69 (44%) set no upper age limit and 79 (51%) stop at 75 or younger; 112 take children under 18; 25 take healthy volunteers.
This study: 8 Years to 18 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
22 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 4 · Phase 3 2 · Phase 4 2
First in 2006; this study’s year is marked. 2 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 30 is below the median of 60 across 508 interventional studies indexed under Heart Defects, Congenital.
Median enrollment 47 across the 22 interventional studies. Of the 15 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
The Hospital for Sick Children is the lead sponsor of 579 studies on the registry; 81 are open to participants now.
Of its 7 completed or terminated interventional studies of FDA-regulated products, 1 (14%) have results posted.
None of the studies under way reaches primary completion within a year.
Among the 22 studies in Heart Defects, Congenital by The Hospital for Sick Children, from their registry updates:
This tab as a report to print or save as PDF → With an account.
SickKids and UHN have developed MedlyPeds which is a smart phone application designed to remotely monitor patients with heart disease. This is a feasibility study which will enroll up to 30 patients with different types of heart disease to see which patient types may benefit the most from MedlyPeds if it were to be used for clinical monitoring. The study is gathering feedback about the app from patients, parents and clinicians to confirm how it needs to be modified to better serve the purpose in a future trial.
This is a prospective cohort study that will enroll up to 30 patients with various types of heart disease and up to 10 clinicians in the MedlyPeds program and follow the participants for 3 months. Quality of life questionnaires will be completed at baseline and 3 months or end of study. Patient participants will complete a questionnaire about MedlyPeds and their experience using the app at 3 month or end of study. A subset of patient participants and clinicians will be asked to complete an interview at the end of the study.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Followed at the Hospital for Sick Children Cardiology Clinic for any of the following reasons:
Exclusion Criteria:
Device: MedlyPeds App
The mobile phone-based telemonitoring system (MedlyPeds) will enable cardiac patients to monitor their weight, blood pressure, and heart rate, using wireless home medical devices. In addition, they will answer questions about their symptoms and wellness using their mobile phone. The device measurements will be automatically and wirelessly transmitted to the mobile phone and then to a data server. Automated and individualized self-care messages, developed with the assistance of healthcare providers, will subsequently be sent to the patient based on the readings and reported symptoms.
Percentage of MedlyPeds App Daily Check-In Completion
The primary outcome for this study is overall app engagement measured by completion of symptom check-ins and entry of clinical information (i.e physiologic parameters) by the subject into the app. The feasibility and acceptability of MedlyPeds will be assessed from feedback from patients, parents and clinicians through the end of study questionnaire and interviews.
Time frame: 3 months
Feasibility and acceptability of Medly Peds
The feasibility and acceptability of MedlyPeds will be assessed from feedback from patients, parents and clinicians through the scoring of usefullness and relevance on the end of study questionnaire.
Time frame: 3 months
Attrition rate
Change in participants completing MedlyPeds check-ins at baseline compared to the final check-in at Month 3 timepoint
Time frame: 3 Months
Medication compliance
Change in estimated number of missed doses of medication from baseline to final check-in
Time frame: 3 Months
Global impression of change
Change in Patients' Global Impression of Change Scale (PGIC) from 1-7. Higher values at post-intervention represent a better outcome.
Time frame: 3 Months
Quality of life related to heart disease
Change in Cardiac PedsQL (Pediatric Quality of Life Inventory) Uses a 5-point Likert scale (0=never, 4=almost always) with 27 questions.
Time frame: 3 Months
Self-management
Change in Adolescent/Young Adult Self-Management and Independence (AMIS II) Scale
Time frame: 3 Months
Plan to share: No
No publications or documents are linked to this record.
Started Jul 2026 (actual). Primary completion is estimated for Dec 2028, 29 months after the start.
Of 208 non-industry interventional studies with no phase under Heart Defects, Congenital, half reached primary completion within 34 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 53. This study's planned 29 months is below that.
Counting every sponsor, half of 226 studies reached it within 34 months; a quarter within 17 and three quarters within 57.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
The Hospital for Sick Children →